A CAGR of 6.5% is forecasted for the global Cancer Diagnostics Market over the assessment period of 2025 through 2034.
Cancer Diagnostics encompasses rise in cancer cases worldwide. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold meaningful shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Diagnostics Market Snapshot
Chapter 4. Global Cancer Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:
5.2.1. Consumables
5.2.1.1. Antibodies
5.2.1.2. Kits & Reagents
5.2.1.3. Probes
5.2.1.4. Other Consumables
5.2.2. Instruments
5.2.2.1. Pathology-based Instruments
5.2.2.1.1. Slide Staining Systems
5.2.2.1.2. Tissue Processing Systems
5.2.2.1.3. Cell Processors
5.2.2.1.4. PCR Instruments
5.2.2.1.5. NGS Instruments
5.2.2.1.6. Microarrays
5.2.2.1.7. Other Pathology-based Instruments
5.2.2.2. Imaging Instruments
5.2.2.2.1. CT Systems
5.2.2.2.2. Ultrasound Systems
5.2.2.2.3. MRI Systems
5.2.2.2.4. Mammography Systems
5.2.2.2.5. Nuclear Imaging Systems
5.2.3. Biopsy Instruments
Chapter 6. Market Segmentation 2: by Technology Estimates & Trend Analysis
6.1. by Technology & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Technology:
6.2.1. IVD Testing
6.2.1.1. Polymerase Chain Reaction (PCR)
6.2.1.2. In Situ Hybridization (ISH)
6.2.1.3. Immunohistochemistry (IHC)
6.2.1.4. Next-generation Sequencing (NGS)
6.2.1.5. Microarrays
6.2.1.6. Flow Cytometry
6.2.1.7. Immunoassays
6.2.1.8. Other IVD Testing Technologies
6.2.2. Imaging
6.2.2.1. Magnetic Resonance Imaging (MRI)
6.2.2.2. Computed Tomography (CT)
6.2.2.3. Positron Emission Tomography (PET)
6.2.2.4. Mammography
6.2.2.5. Ultrasound
6.2.3. Biopsy Technique
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Melanoma
7.2.5. Other Cancers
Chapter 8. Market Segmentation 4: by End-user Estimates & Trend Analysis
8.1. by End-user & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-user:
8.2.1. Hospitals
8.2.2. Diagnostic Laboratories
Chapter 9. Cancer Diagnostics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.1.2. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.1.3. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.1.4. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.1.5. North America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.2. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.3. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.4. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.2.5. Europe Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.2. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.3. Asia-Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.4. Asia-Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.3.5. Asia Pacific Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.2. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.3. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.4. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.4.5. Latin America Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.2. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.3. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.4. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
9.5.5. Middle East & Africa Cancer Diagnostics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Abbott Laboratories,
10.2.2. Agilent Technologies Inc.,
10.2.3. AMOY Diagnostics Co Ltd.,
10.2.4. Astellas Pharma Inc. (Japan)
10.2.5. BD
10.2.6. BiocartisNV,
10.2.7. bioMérieux SA (France)
10.2.8. Bristol-Myers Squibb Company (U.S.)
10.2.9. Cancer Diagnostics Inc.,
10.2.10. Danaher Corporation,
10.2.11. DiagnoCure Inc. (Canada)
10.2.12. DiaSorin S.P.A.,
10.2.13. Excat Science
10.2.14. F. Hoffmann-La Roche Ltd.
10.2.15. FUJIFILM Corporation,
10.2.16. GE Healthcare
10.2.17. Genomic Health, Inc. (U.S.)
10.2.18. GSK plc. (U.K.)
10.2.19. Hologic, Inc.
10.2.20. Illumina, Inc.
10.2.21. Koninklijke Philips N.V. (Philips)
10.2.22. Lilly (U.S.)
10.2.23. Merck KGaA, (Germany)
10.2.24. Myriad Genetics Inc.,
10.2.25. Novartis AG (Switzerland)
10.2.26. Pfizer, Inc. (U.S.)
10.2.27. Qiagen N.V.
10.2.28. Quest Diagnostics Incorporated. (U.S.)
10.2.29. Quidel Corporation,
10.2.30. Roche Diagnostics,
10.2.31. Siemens Healthcare GmbH
10.2.32. Thermo Fisher Scientific, Inc.
10.2.33. Other Prominent Players